Not intended to diagnose, treat, cure, or prevent any disease
i , Conditioned Taste Avoidance (CTA) in lean wildtype and Vglut2-GLP-1R KO mice 24 h after single s.c
For travel questions, contact PlexusDx support for personalized guidance on maintaining your medication's integrity
Additionally, each vial contains 10mg of highly stable lyophilised powder
Based on the research and clinical trials, here are the disease states and associated risk reductions with GLP-1 medications: Cardiovascular Disease: Major adverse cardiovascular events (MACE): 20-26% reduction Heart attack: ~20% reduction Stroke: ~20% reduction Cardiovascular death: ~15-20% reduction Heart Failure: Heart failure with preserved ejection fraction (HFpEF): Improved symptoms, exercise tolerance, and body composition Heart failure hospitalizations: Reduced (specific percentages vary by study) Kidney Disease: Progression to end-stage renal disease: 20-30% reduction Decline in eGFR: Slowed progression Type 2 Diabetes: Progression from prediabetes to diabetes: Reduced risk (specific percentage varies) Liver Disease: NAFLD/NASH improvement: Reduced liver fat and inflammation Liver enzyme normalization: Significant improvement in ALT/AST Obesity-Related Complications: Body weight reduction: 10-15% (semaglutide), 15-22% (tirzepatide) Visceral fat reduction: Substantial decrease Metabolic Syndrome Components: Blood pressure: 5-10 mmHg reduction in systolic BP Triglycerides: 20-30% reduction Insulin resistance: Significant improvement Cancer: (emerging data) Overall cancer risk: Potential reduction (10-20% suggested in some observational studies) Specific cancers linked to obesity/metabolic dysfunction: Reduced risk observed Neurodegeneration: (preliminary data) Alzheimers disease progression: Some trials are ongoing, but recent data have been unpromising
